Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Active Surveillance for Localized Prostate Cancer
This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.
The Big Scare
None
Management of Prostate Cancer
This book provides an exhaustive review of the current state of the art in the management of prostate cancer, from screening to treatment. A particular feature is the emphasis placed on the value of a multidisciplinary approach. The opening chapters address basic aspects including epidemiology, biology, and chemoprevention. The role of individual and mass screening is carefully appraised, and diagnosis, clinical work-up, and the role of active surveillance are discussed in detail. Subsequent chapters are devoted to each of the therapies that may be employed, including open and robotic laparoscopic radical prostatectomy, the various forms of radiation therapy, high-intensity focused ultrasound, cryotherapy, hormonal therapy, and targeted therapies and vaccination. Up-to-date data from clinical trials are included. The editors are members of the EORTC who have coordinated phase III EORTC trials and have worldwide reputations.
The Cancer Journey
"This work is a guide to everything cancer from A to Z, simplifying ALL cancer concepts for patients, families, and the non-oncologist"--
Management of Prostate Cancer
The thoroughly updated and revised third edition of Management of Prostate Cancer provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer. Highlighting the latest major advances in the field, the book includes chapters on the most controversial areas of prostate cancer – screening, chemoprevention, and active surveillance; updated chapters on genetic risk and progression, biopsy schemes, treatment of complications, and comparative treatment outcomes for surgery; and new chapters on risk factors, new markers, nomograms, and focal therapy. This volume also features overviews of new and emerging drugs and treatment paradigms for castrate resistant disease, advances that promise to extend life and perhaps even cure a subset of men with metastatic disease. With its comprehensive illustrations and contributions from renowned experts in the field, Management of Prostate Cancer, 3rd Edition is an invaluable resource for practitioners in the treatment of prostate cancer.
Management of Urologic Cancer
Immer mehr Urologen und Onkologen entscheiden sich beim Management urologischer Krebserkrankungen für den Erhalt und nicht die Entfernung des betroffenen Gewebes. Dieses Fachbuch erläutert alle verfügbaren Optionen und zeigt das bestmögliche Patientenmanagement. Herausgeber Mark Schoenberg ist ein international anerkannter Experte auf diesem neuen, aufregenden Gebiet und hat ein herausragendes Team zusammengestellt, zu dem einige der führenden Urologen und Onkologen aus Nordamerika und Europa gehören.
Prostate Cancer
Prostate Cancer, Science and Clinical Practice, Second Edition, continues to be an important translational reference that bridges the gap between science and clinical medicine. It reviews the biological processes that can be implicated in the disease, reviews current treatments, highlights the pitfalls where relevant, and examines the scientific developments that might result in future treatments. Key chapters from the previous edition have been updated, and a plethora of new chapters describe new concepts of prostate cancer biology and newly developed therapeutics. Each chapter has been written by internationally recognized specialists on prostate cancer epidemiology, genetic susceptibility...
Bioidentical Hormones 101
American medicine has lost its way. In Bioidentical Hormones 101, author Dr. Jeffrey Dach uncovers the ills in today’s health care system and suggests ways to get it back on track. Through a series of articles that originally appeared on his Internet blog, Dach provides evidence that bioidentical hormones are safer and more effective than synthetic hormones. He describes how to win the information war and take control of your health. Questioning the prevailing medical dogma, he covers a wide range of topics related to health and health care: Natural thyroid Iodine supplementation Selenium Dangers of GMO food Avoiding bad drugs Limitations of cancer screening with mammograms PSA testing Thyroid ultrasound Low-dose naltrexone Future of medicine Health insurance companies Dispensing the truth about drugs, health care, and medicine, Bioidentical Hormones 101 uses information to empower America to embrace a more holistic approach to health care.
The Prostate Cancer Dilemma
This text provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative and in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma...
